CN106924272A - Purposes of the salicylic acid glucosides methyl in prevention and/or systemic lupus erythematosus and its complication medicine is prepared - Google Patents
Purposes of the salicylic acid glucosides methyl in prevention and/or systemic lupus erythematosus and its complication medicine is prepared Download PDFInfo
- Publication number
- CN106924272A CN106924272A CN201611259895.6A CN201611259895A CN106924272A CN 106924272 A CN106924272 A CN 106924272A CN 201611259895 A CN201611259895 A CN 201611259895A CN 106924272 A CN106924272 A CN 106924272A
- Authority
- CN
- China
- Prior art keywords
- lupus
- complication
- lupus erythematosus
- systemic lupus
- salicylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 201000000596 systemic lupus erythematosus Diseases 0.000 title claims abstract description 25
- 229930182478 glucoside Natural products 0.000 title claims abstract description 23
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 title claims abstract description 22
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229960004889 salicylic acid Drugs 0.000 title claims abstract description 22
- 230000002265 prevention Effects 0.000 title claims abstract description 17
- 206010025135 lupus erythematosus Diseases 0.000 claims abstract description 75
- -1 Salicylic acid glucosides methyl compound Chemical class 0.000 claims abstract description 22
- 206010003246 arthritis Diseases 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 206010041649 Splenic injury Diseases 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 208000026278 immune system disease Diseases 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 230000009885 systemic effect Effects 0.000 claims description 13
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical group Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 150000002016 disaccharides Chemical group 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000004043 trisaccharides Chemical class 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000013265 extended release Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 241000282461 Canis lupus Species 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000025309 Hair disease Diseases 0.000 claims 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 16
- 210000000952 spleen Anatomy 0.000 abstract description 14
- 230000008506 pathogenesis Effects 0.000 abstract description 7
- 210000005084 renal tissue Anatomy 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 5
- 230000003907 kidney function Effects 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 3
- 235000008216 herbs Nutrition 0.000 abstract description 3
- 230000036737 immune function Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 2
- 239000000178 monomer Substances 0.000 abstract 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 40
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 20
- 229940079593 drug Drugs 0.000 description 17
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 14
- 229960001138 acetylsalicylic acid Drugs 0.000 description 13
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical group O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 13
- 229940109239 creatinine Drugs 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000016918 Complement C3 Human genes 0.000 description 3
- 108010028780 Complement C3 Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002601 glomerular mesangium Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Salicylic acid glucosides methyl compound and its pharmaceutically acceptable salt the invention discloses a class as shown in formula (1) are preparing the medicinal usage of prevention and/or systemic lupus erythematosus and its complication.In the present invention, the pharmacological action that salicylic acid glucosides methyl has to be reduced the expression of autoantibody and inflammatory factor in lupus mice body, improve immunologic function；With the effect for slowing down lupus arthritis sample pathogenesis；Pharmacological action with immune complex deposit, improvement lupus mice renal function in reduction lupus mice renal tissue；Effect with protection lupus mice spleen function.Salicylic acid glucosides methyl compound is to extract the monomeric compound of separation in folks of china Chinese traditional herbs Caulis et folium gaultheriae yunnanensis, has the advantages that toxicity is low, extraction process is simple, synthetic route is ripe；Its raw material resources is wide, and easily a large amount of preparations, it is a kind of traditional Chinese medicine monomer of the complication such as more satisfactory new systemic lupus erythematosus and its immune dysfunction, lupus arthritis, LN, systemic lupus erythematosus splenic injury with good applicating and exploitation prospect.
Description
Technical field
The present invention relates to the new pharmacological action of salicylic acid glucosides methyl compound and its pharmaceutically acceptable salt, and
Salicylic acid glucosides methyl compound and its pharmaceutically acceptable salt prepare prevention and treatment systemic loupus erythematosus and its
Application in complication disease medicament；Category pharmaceutical technology field.
Technical background
Systemic loupus erythematosus (systemic lupus erythematosus, SLE) is a kind of product with autoantibody
The autoimmune connective tissue disease for being deposited as major pathologic features of raw and immune complex, be it is a kind of be difficult to cure it is slow
The health of the mankind in property disease, serious harm.Clinical characteristics are the tissue damage of general, most significantly
I.e. so-called facial rash (butterfly macules).Except skin, systemic loupus erythematosus generally has an effect on nearly all important group
(such as joint) and organ (such as heart, liver, brain, kidney and lung) are knitted, hematological system and central nervous system are also often that body is mainly received
Tired part.Estimate according to U.S.'s lupus foundation, patient of the whole America with systemic loupus erythematosus is not less than 1,500,000, it is annual new
Increase case up to 1.6 ten thousand.In China and world wide, also about 100 and 5,000,000 people endure systemic loupus erythematosus to the fullest extent
Torment.Systemic loupus erythematosus is a kind of chronic disease for expending a large amount of medical resources.In the U.S., Patients with SLE
Year per capita treatment total cost (in hospital, outpatient service and pharmacy) be up to 29,232 dollars, significantly larger than other non-systemics are red
Expense produced by the patients with chronic diseases of yabbi sore.
Clinically systemic loupus erythematosus common drug mainly includes NSAIDs, antimalarial, glucocorticoid, exempts from
Epidemic disease inhibitor and biological agent.These medicines only being capable of relief of symptoms to a certain extent, it is impossible to thorough cure diseases, while again
Have the shortcomings that toxic and side effect is big, adverse reaction is more.
Therefore, the research for Therapy for Systemic Lupus Erythematosus medicine not only has huge social benefit, and can be with
Substantially mitigate the financial burden of state's family and home, be very urgent and necessary.
In Chinese invention patent application (denomination of invention：" salicylic acid glucosides methyl compound, its synthetic method and use
On the way ", application number：200910082224.0；Publication number CN101863934A；Publication date 2010-10-20) in disclose a class water
Poplar acid glucosides methyl compound, discloses application of this kind of compound in antipyretic, anti-inflammatory and analgesic is prepared.Without public affairs
Open its application in prevention and/or systemic lupus erythematosus and its complication product is prepared.
The content of the invention
The technical problem to be solved in the present invention is to provide salicylic acid glucosides methyl compound and its pharmaceutically acceptable
Application of the salt in prevention and/or systemic lupus erythematosus and its complication product is prepared.
To solve above technical problem, the invention provides following technical scheme：
The first aspect of technical solution of the present invention there is provided the salicylic acid glucosides methyl compound as shown in formula (1)
And its application of the pharmaceutically acceptable salt in prevention and/or systemic lupus erythematosus and its complication product is prepared；
R is selected from the disaccharides or trisaccharide that monose, monose are constituted, wherein described monose includes glucose, fructose, galactolipin；
Further, described disaccharides includes lactose, maltose, sucrose.
Wherein, described prevention and/or systemic lupus erythematosus and its complication is selected from immune dysfunction, lupus
Arthritis, LN, systemic lupus erythematosus splenic injury；Described product includes medicine, food, health products.
Technical solution of the present invention second aspect there is provided a kind of pharmaceutical composition and prepare prevention and/or treatment system
Application in lupus erythematosus and its complication product, it is characterised in that the chemical combination shown in the logical formula (I) containing treatment effective dose
Thing and pharmaceutically acceptable carrier or auxiliary material,
R is selected from the disaccharides or trisaccharide that monose, monose are constituted, wherein described monose includes glucose, fructose, galactolipin；
Further, described disaccharides includes lactose, maltose, sucrose.
Wherein, described prevention and/or systemic lupus erythematosus and its complication is selected from immune dysfunction, lupus
Arthritis, LN, systemic lupus erythematosus splenic injury；Described product includes medicine, food, health products.
Further, the pharmaceutical composition described in technical solution of the present invention second aspect also include with other active materials with
Any ratio shares the pharmaceutical composition being made.
Further, above-described pharmaceutical composition is selected from following formulation：Solution, suspension, freeze-dried powder, breast
Agent, pill, capsule, powder, sustained release preparation, control release preparation, extended release preparation and microsome delivery system.
Pharmaceutical composition described in second aspect present invention, prepares, using several approach to tested with known method
Person applies, including but not limited to parenteral, oral, part, intracutaneous, intramuscular, intraperitoneal, subcutaneous, vein, intra-nasal route.
Salicylic acid glucosides methyl compound can be prepared by known methods and obtain in the present invention.
The pharmaceutical composition of salicylic acid glucosides methyl compound of the invention it is optional can be by any conventional method
Prepared with one or more pharmaceutically acceptable carrier and/or excipient.Therefore, salicylic acid glucosides methyl compound and it
Pharmaceutically acceptable salt can especially be formulated as example sucking or be blown into (by mouth or nose) or oral, containing changing, parenteral or rectum
Administration.
The pharmaceutical composition of salicylic acid glucosides methyl compound can also use solution, suspension, emulsion, pill, glue
Capsule, powder, control release or extended release preparation.These preparations are by the salicylic acid glucosides methyl class chemical combination containing therapeutically effective amount
Thing, preferably purified form, and appropriate carrier, in the form of providing to the appropriate administration of patient.
Advantageous Effects：
The present invention sets up mouse system lupus erythematosus model by intraperitoneal injection norphytane (pristane), after modeling
1st month to carrying out examination into mould mouse, the failed mouse of deleting madel, and model success mouse is grouped at random,
Proceed by pharmaceutical intervention within the 45th day after model is prepared.During whole experiment, every other month to lupus mice serum
The expression of the autoantibodies such as middle DNA is dynamically determined, while also being carried out to lupus mice arthritis sample pathogenesis
Effective monitoring.6th month after model is prepared, mice serum and main internal organs are collected, from splenic injury and kidney
The aspects such as function damage assess effective alleviations and therapeutic action of the DL0309 to lupus mice pathogenesis.Tested more than,
Present invention firstly discovers that salicylic acid glucosides methyl compound has reduces autoantibody and inflammatory factor in lupus mice body
Expression, the effect for improving immunologic function；With the effect for slowing down lupus arthritis sample pathogenesis；With reducing, lupus is small
Immune complex deposit, the effect of improvement lupus mice renal function in mouse renal tissue；With protection lupus mice spleen function
Effect, can be applied to prepare prevention, alleviate and/or systemic lupus erythematosus and its immune dysfunction, lupus joint
The product of the complication such as inflammation, LN, systemic lupus erythematosus splenic injury.
And medicine salicylic acid glucosides methyl compound of the invention be folks of china Chinese traditional herbs Caulis et folium gaultheriae yunnanensis in carry
The monomeric compound of separation is taken, has the advantages that toxicity is low, extraction process is simple, synthetic route is ripe；Its raw material resources is wide
It is wealthy, and easily a large amount of preparations, with application and DEVELOPMENT PROSPECT well.
Brief description of the drawings
Influence (the A of itself DNA antibody expression in the lupus mice body that Fig. 1 .DL0309 are induced pristane：IgG types
DNA autoantibodies；B：IgM type DNA autoantibodies).
Influence (the A of itself Sm antibody expression in the lupus mice body that Fig. 2 .DL0309 are induced pristane：IgG types Sm
Autoantibody；B：IgM type Sm autoantibodies).
Influence (the A of itself HAB expression in the lupus mice body that Fig. 3 .DL0309 are induced pristane：IgG
Type histone autoantibody；B：IgM type histones autoantibody).
The influence of IL-6 (A) and total IgG (B) expression in the lupus mice body that Fig. 4 .DL0309 are induced pristane.
The influence of the lupus mice metapedes volume that Fig. 5 .DL0309 are induced pristane.
DL0309 is observed under Fig. 6 .X- light radiographies effect is effectively improved to lupus mice hindlimb joints deformity and swelling.
Improvement result (the A of the lupus mice renal function that Fig. 7 .DL0309 are induced pristane：Creatinine in serum contains
Amount；B：The ratio of total protein and creatinine in urine specimen).
Fig. 8 renal histopathologies detect (H＆E dyeing) (a- control groups；B- model groups；C- model groups；D- aspirin
Group；E- metacortandracin groups；F- low dose groups；G- middle dose groups；H- high doses group).
Fig. 9 renal histopathologies detect (PAS dyeing) (a- control groups；B- model groups；C- model groups；D- aspirin
Group；E- metacortandracin groups；F- low dose groups；G- middle dose groups；H- high doses group).
The deposition of total IgG compound in Figure 10 renal tissues.
The deposition of C3 complement complex in Figure 11 renal tissues.
Influences of Figure 12 .DL0309 to lupus mice spleen index.
Figure 13 spleen tissues pathology detect (H＆E dyeing) (a- control groups；B- model groups；C- model groups；d-DL0309
Low dose group；E-DL0309 middle dose groups；F-DL0309 high dose groups；G- aspirin groups；H- metacortandracins group)
Specific embodiment
Salicylic acid glucosides methyl compound is further illustrated with reference to the present invention to prevent in vivo, alleviate and/or control
Treat pharmacological action and the medicinal usage of systemic loupus erythematosus and its complication.
Following embodiments illustrate the present invention in more detail, are not any limitation of the invention.
Experimental example 1：The systemic loupus erythematosus mouse model induced by norphytane (pristane) is a kind of classical, wide
It is the mouse model of accreditation, is commonly used to assess the pharmacological action of anti-lupus medicine.The raising of mouse, packet and administrations are such as
Under：Inbred strais BALB/c female mices (SPF grades, 7~8 week old) are purchased from Beijing Vital River Experimental Animals Technology Co., Ltd.
(quality certification number：SCXK (capital) 2012-0001；Sequence number：11400700048526).BALB/c mouse since before modeling 1 week, extremely
Before experiment terminates (after modeling 6 months), raise always in institute of Materia Medica,Chinese Academy of Medical Sciences Experimental Animal Center barrier system
System, 5~7/cage.Rearing conditions are：25 DEG C of constant temperature, 50% relative humidity, conventional feed and free waters and 12h illumination/
Dark alternate cycles.
1st month after modeling, according to the expression of internal autoantibody to carrying out examination into mould mouse, and will be into
Mouse is grouped mould at random, 12/group.Respectively control group, model group, DL0309 low dose groups (200mg/kg body weight),
DL0309 middle dose groups (400mg/kg body weight), DL0309 high doses group (800mg/kg body weight), positive drug aspirin group
(303mg/kg body weight) and positive drug metacortandracin group (5mg/kg body weight).The 45th day after modeling starts, according to above-mentioned dosage
It is administered orally, 1 times/day.Administered volume is 0.2mL/10g body weight.Wherein control group and model group synchronously give
The CMC-Na solution of volume.
(1) influence that itself DNA antibody is expressed in the lupus mice body that detection DL0309 is induced pristane.
After modeling the 1st, 2 ... 6 months, blood is taken by cutting tail, and serum and haemocyte are separated.Using
ELISA method is measured to DNA, Sm, HAB level in serum sample.Draw each group serum sample in itself DNA,
Sm, HAB relative expression levels with the time performance graph (see Fig. 1, Fig. 2 and Fig. 3), lupus model mice serum
The expression of the above-mentioned autoantibody of two kinds of forms of middle IgG and IgM significantly raises (* P<0.05 or * * P<0.01)；It is middle and high
The DL0309 of dosage, positive drug aspirin can reduce DNA-IgG/IgM, Sm-IgG/ in lupus mice body with metacortandracin
The rising of the autoantibodies level such as IgM and histone-IgG/IgM, with the difference of model group have statistical significance (#P<
0.05,##P<0.01 or###P<0.001), illustrate that Oral administration of compounds DL0309 can effectively suppress in lupus mice body itself
The generation of antibody.
(2) shadow of inflammatory cytokine IL-6 levels in the lupus mice serum that DL0309 is induced pristane is detected
Ring.
2nd month (namely carrying out the 15th day after pharmaceutical intervention) after modeling, determines IL-6 in each group mice serum
Expression (see Fig. 4 A).IL-6 this important inflammatory mediator is detected obvious height in lupus model mice serum
Expression (* * P<0.01)；The DL0309 of high dose, positive drug aspirin can significantly reduce lupus mice serum with metacortandracin
Middle IL-6 expression (#P<0.05 or##P<0.01), illustrate that Oral administration of compounds DL0309 can effectively suppress lupus small
The expression of inflammatory cytokine in mouse body.
(3) influence of total IgG level in the lupus mice serum that DL0309 is induced pristane is detected.
After modeling the 1st, 2 ... 6 months, the content of total IgG in each group mice serum is determined (see figure by ELISA
4B).The content of total IgG rising over time progressively in lupus mice serum, 2nd month after modeling start with
Control group is compared and shows significant difference (* * P<0.01)；The DL0309 of middle and high dosage, positive drug aspirin and metacortandracin
Can significantly reduce total IgG in lupus mice serum expression (#P<0.05 or##P<0.01)。
(4) influence of the lupus mice foot swelling degree that detection DL0309 is induced pristane.
6th month after modeling, mouse metapedes same position is rule by independent experiment personnel, mouse metapedes is dipped in
In measuring cup liquid, and line position and liquid level is set to maintain an equal level, after measuring and record mouse using toy toes volume measuring apparatus
Sufficient volume (see Fig. 5).The average external volume of lupus mice metapedes significantly raises (* * P relative to control group<0.01)；Middle and high dosage
DL0309, positive drug aspirin and metacortandracin can significantly reduce lupus mice metapedes volume (#P<0.05 or##P<
0.01), illustrate that Oral administration of compounds DL0309 can effectively suppress foot swelling degree after lupus mice.
(5) influence of the lupus mice arthritis sample pathogenesis that detection DL0309 is induced pristane.
6th month after modeling, mouse hind leg is placed under X- light and is observed.Lupus model mouse metapedes is in X- light
Under visible obvious deformity, while also observing that obvious swelling at ankle；And the DL0309 groups of middle and high dosage, positive drug
Aspirin does not observe obvious such phenomenon (see Fig. 6) with metacortandracin group, illustrates Oral administration of compounds DL0309 energy
It is enough effectively to alleviate lupus mice arthritis sample pathogenesis.
(6) influence of the lupus mice creatinine in serum content that detection DL0309 is induced pristane.
6th month after modeling, mice serum is collected, with SOD enzymatic assays creatinine in serum content (see Fig. 7 A).Wolf
Sore model mice creatinine in serum content is significantly raised；The DL0309 of high dose, positive drug aspirin can have with metacortandracin
Effect reduces creatinine in serum content.
(7) influence of total protein content in the lupus mice urine that DL0309 is induced pristane is detected.
6th month after modeling, mouse urine is collected, with creatinine content in SOD enzymatic assays urines, surveyed with BCA methods
Determine total protein content in urine.By calculating the two ratio (see Fig. 7 B), it is seen that in lupus model mouse urine in unit creatinine
The content of total protein is significantly raised；The DL0309 of high dose, positive drug aspirin can effectively reduce unit flesh with metacortandracin
The content of total protein in acid anhydride.
(8) influence that the lupus mice Pathological that detection DL0309 is induced pristane changes.
6th month after modeling, each group mouse kidney is collected, carry out pathologic finding.Through H＆E dyeing (see Fig. 8), under mirror
Observing in visible lupus model mouse kidney tissue has massive inflammatory cells infiltrated, and glomerular mesangium broadens, and capillary wall increases
Thickness, shows typical glomerulonephritis feature；The DL0309 of high dose, positive drug aspirin and metacortandracin can be obvious
Improve lupus mice this pathological change.Through PAS dyeing (see Fig. 9), blood capillary in the visible normal murine glomerular of Microscopic observation
Pipe loop is thin and clear, and capillary loops is substantially thickened in the glomerulus of lupus lesion, and glomerulus swelling causes capsula glomeruli narrow, together
Shi Kejian basilar memebranes are disorderly, the pathological change such as renal tubule is thickened；The DL0309 of high dose, positive drug aspirin and metacortandracin energy
Enough obvious this pathological changes of improvement lupus mice.Above-mentioned experiment confirms DL0309 to lupus mice kidney from pathologic angle
The protective effect of dirty damage.
(9) influence of immune complex deposit in the lupus mice nephridial tissue that DL0309 is induced pristane is detected.
6th month after modeling, each group mouse kidney is collected, carry out indirect IF staining.It is aobvious in 200 times of fluorescence
Micro- Microscopic observation (see Figure 10), lupus model mouse kidney tissue especially glomerulus position can be inspired it is strong red glimmering
Light, illustrates the substantial amounts of total IgG compound of glomerulus site deposition；The DL0309 of high dose, positive drug aspirin and Po Ni
Pine can significantly reduce the deposition of total IgG compound in lupus mice nephridial tissue.Seen under 400 times of laser confocal microscopes
Examine (see Figure 11), lupus model murine glomerular can be inspired strong green fluorescence, illustrate that glomerulus site deposition is big
The C3 complement complex of amount；The DL0309 of high dose, positive drug aspirin and metacortandracin can significantly reduce lupus mice
The deposition of C3 complement complex in nephridial tissue.Above-mentioned experiment confirms that DL0309 is immunized again in can reducing lupus mice nephridial tissue
The deposition of compound, also further illustrates the mechanism that DL0309 protects lupus mice renal function.
(10) influence of lupus mice spleen index, spleen pathological change that detection DL0309 is induced pristane.
6th month after modeling, mouse spleen is collected, calculate the spleen index of each group mouse than body weight with spleen weight
(see Figure 12).Lupus model mouse spleen index is increased (* * P by about one time compared to control group<0.01)；High dose
DL0309, positive drug aspirin and metacortandracin can significantly reduce lupus mice spleen index rising (#P<0.05 or##P<
0.01), illustrate that DL0309 can play significant protective effect to the spleen of lupus mice.Also entered by histopathological examination
One step confirms above-mentioned conclusion.Microscopic observation is visible (Figure 13), and cell paraplasm in lupus model mouse boosting tissue, spleen is white
Pith knot structure is in multinodular and expansion；Positive drug aspirin and metacortandracin and DL0309 can significantly improve this pathology
Change.
Integral animal experiment result shows that lupus mice body is interior itself to be resisted salicylic acid glucosides methyl compound with reducing
The expression of body and inflammatory factor, the effect for improving immunologic function；With the effect for slowing down lupus arthritis sample pathogenesis；
Effect with immune complex deposit, improvement lupus mice renal function in reduction lupus mice renal tissue；With protection wolf
The effect of sore mouse spleen function.
In sum, salicylic acid glucosides methyl compound have prevention, alleviate and/or systemic lupus erythematosus and
The effect of its complication, salicylic acid glucosides methyl compound is to extract the list of separation in folks of china Chinese traditional herbs Caulis et folium gaultheriae yunnanensis
Body compound, has the advantages that toxicity is low, extraction process is simple, synthetic route is ripe；Its raw material resources is wide, and easily big
Prepared by amount, with application and DEVELOPMENT PROSPECT well, can be applied to prepare prevention, alleviate and/or systemic lupus erythematosus
And its product of the complication such as immune dysfunction, lupus arthritis, LN, systemic lupus erythematosus splenic injury.
Claims (10)
1. as lead to formula (I) shown in salicylic acid glucosides methyl compound and its pharmaceutically acceptable salt prepare prevention and/
Or the application in systemic lupus erythematosus and its complication product；
R is selected from monose, disaccharides, the trisaccharide of monose composition, wherein described monose includes glucose, fructose, galactolipin, it is described
Disaccharides includes lactose, maltose, sucrose.
2. application according to claim 1, it is characterised in that described prevention and/or systemic lupus erythematosus and its simultaneously
Hair disease is selected from immune dysfunction.
3. application according to claim 1, it is characterised in that described systemic loupus erythematosus and its complication is closed selected from lupus
Section is scorching.
4. application according to claim 1, it is characterised in that described systemic loupus erythematosus and its complication are selected from systemic lupus erythematosus
Ephritis.
5. application according to claim 1, it is characterised in that described systemic loupus erythematosus and its complication are selected from systemic lupus erythematosus
Splenic injury.
6. application according to claim 1, it is characterised in that described product includes medicine, food, health products.
7. application of a kind of pharmaceutical composition in prevention and/or systemic lupus erythematosus and its complication product is prepared,
Characterized in that, compound and pharmaceutically acceptable carrier or auxiliary material shown in the logical formula (I) containing treatment effective dose,
R is selected from monose, disaccharides, the trisaccharide of monose composition, wherein described monose includes glucose, fructose, galactolipin, it is described
Disaccharides includes lactose, maltose, sucrose.
8. application according to claim 7, it is characterised in that described pharmaceutical composition also includes with other materials with any ratio
Example shares the pharmaceutical composition being made.
9. according to the application of claim any one of 7-8, it is characterised in that described prevention and/or treatment system erythema wolf
Sore and its complication are selected from immune dysfunction, lupus arthritis, LN, systemic lupus erythematosus splenic injury；Described product
Including medicine, food, health products.
10. pharmaceutical composition according to claim 7, it is characterised in that described pharmaceutical composition is selected from following formulation：It is molten
Liquid, suspension, freeze-dried powder, emulsion, pill, capsule, powder, sustained release preparation, control release preparation, extended release preparation and micro-
Plastochondria delivery system.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015110323140 | 2015-12-31 | ||
| CN201511032314 | 2015-12-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106924272A true CN106924272A (en) | 2017-07-07 |
| CN106924272B CN106924272B (en) | 2021-04-13 |
Family
ID=59444015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611259895.6A Active CN106924272B (en) | 2015-12-31 | 2016-12-31 | Application of methyl salicylate glucoside in preparation of medicines for preventing and/or treating systemic lupus erythematosus and complications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106924272B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003016551A2 (en) * | 2001-08-16 | 2003-02-27 | Boyce Thompson Institute For Plant Research, Inc. | Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof |
| CN1727354A (en) * | 2004-07-30 | 2006-02-01 | 丁怡 | Compound in category of trioside methyl salicylate, oside ester saccharide |
| WO2008012603A1 (en) * | 2006-07-26 | 2008-01-31 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate |
| CN101128117A (en) * | 2005-01-03 | 2008-02-20 | 吕伊·J·于 | Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
| WO2009080821A2 (en) * | 2007-12-21 | 2009-07-02 | Giuliani International Limited | Receptor targeting ligands |
| CN101863934A (en) * | 2009-04-20 | 2010-10-20 | 中国医学科学院药物研究所 | Salicylic acid glucosides methyl compound, and synthesis method and purposes thereof |
| CN102526080A (en) * | 2011-12-12 | 2012-07-04 | 北京协和药厂 | Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof |
-
2016
- 2016-12-31 CN CN201611259895.6A patent/CN106924272B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003016551A2 (en) * | 2001-08-16 | 2003-02-27 | Boyce Thompson Institute For Plant Research, Inc. | Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof |
| CN1727354A (en) * | 2004-07-30 | 2006-02-01 | 丁怡 | Compound in category of trioside methyl salicylate, oside ester saccharide |
| CN101128117A (en) * | 2005-01-03 | 2008-02-20 | 吕伊·J·于 | Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
| WO2008012603A1 (en) * | 2006-07-26 | 2008-01-31 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate |
| WO2009080821A2 (en) * | 2007-12-21 | 2009-07-02 | Giuliani International Limited | Receptor targeting ligands |
| CN101863934A (en) * | 2009-04-20 | 2010-10-20 | 中国医学科学院药物研究所 | Salicylic acid glucosides methyl compound, and synthesis method and purposes thereof |
| CN102526080A (en) * | 2011-12-12 | 2012-07-04 | 北京协和药厂 | Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof |
Non-Patent Citations (6)
| Title |
|---|
| RASMUSSEN S ET AL.: "Effect of Acetylsalicylic Acid on Renal Function in Systemic Lupus Erythematosus", 《EUR J CLIN PHARMACOL》 * |
| ZHANG X ET AL.: "Anti-inflammation effect of methyl salicylate 2-O-β-D-lactoside on adjuvant induced-arthritis rats and lipopolysaccharide (LPS)-treated murine macrophages RAW264.7 cells", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
| ZHAO M ET AL.: "Total glucosides of paeony induces regulatory CD4(+)CD25(+) T cells by increasing Foxp3 demethylation in lupus CD4(+) T cells", 《CLIN IMMUNOL》 * |
| 梁琳琅 等: "系统性红斑狼疮性关节炎", 《中国实用乡村医生杂志》 * |
| 闫有功 等: "系统性红斑狼疮与抗磷脂抗体综合症", 《华南国防医学杂志》 * |
| 黄超 等: "水杨酸甲酯糖苷抗大鼠急性胸膜炎的作用研究", 《中国药理学通报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106924272B (en) | 2021-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108888670A (en) | A kind of segmented intestine targeted capsule that treating ulcerative colitis and its preparation process | |
| US8003139B2 (en) | Pharmaceutical composition for treating rheumatism, and method of making same | |
| ES2783879T3 (en) | Dimethylaminomycheliolide for use in the treatment of pulmonary fibrosis | |
| CN102293842B (en) | Preparation for treating ulcerative colitis and preparation method thereof | |
| CN101991811B (en) | Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof | |
| CN101254186A (en) | Medicament use of myricetin | |
| CN105233150A (en) | Traditional Chinese medicine composition and application thereof | |
| CN106924272A (en) | Purposes of the salicylic acid glucosides methyl in prevention and/or systemic lupus erythematosus and its complication medicine is prepared | |
| CN101816670A (en) | New medical application of beta-sodium aescinate | |
| CN103830288B (en) | Match certain herbaceous plants with big flowers extractive of general flavone and its production and use | |
| CN105535011A (en) | Applications of mushroom mycelium polysaccharides | |
| CN110038002A (en) | Salviandic acid A prevents and treats the purposes of muscular atrophy, myopathy and muscle skeleton complication | |
| CN110292607B (en) | Traditional Chinese medicine composition for treating hypertension complicated with left ventricular hypertrophy and preparation method thereof | |
| CN103417907A (en) | Applications of traditional Chinese medicine composition in preparation of drug used for inhibiting angiogenesis | |
| CN104095843B (en) | Arctigenin is preparing the application in treating digestive tract ulcer disease medicament | |
| CN111544473A (en) | Refined coronary heart disease granule extraction preparation process for treating coronary heart disease and angina pectoris, traditional Chinese medicine and extract thereof | |
| CN103830662B (en) | A kind of application of Chinese medicine composition in treatment medicine for treating rheumatoid arthritis is prepared | |
| CN100389799C (en) | Tibetan medicine for relieving pain and its preparing method | |
| CN107802632B (en) | Traditional Chinese medicine effective component composition for treating rheumatic arthritis and rheumatoid arthritis and application thereof | |
| CN102716424A (en) | Breast nodule treatment medicine composition and preparation process and application thereof | |
| CN102240359B (en) | Traditional Chinese medicine for preventing and treating recurrence of esophageal cancer after radiotherapy and resisting side reactions of radiotherapy | |
| CN105726893A (en) | Pharmaceutical composition for treating chronic renal failure, as well as preparation method and application thereof | |
| CN105168484A (en) | Traditional Chinese medicine composition for treating female chronic urinary tract infection complicated with pelvic cavity pain | |
| CN104189365B (en) | Treat the Chinese medicine composition and its preparation and preparation method of human body pain | |
| CN104644769A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |